Research Article

Reevaluation of Acromegalic Patients in Long-Term Remission according to Newly Proposed Consensus Criteria for Control of Disease

Table 3

Comparison of metabolic and comorbid data between patients with postglucose GH nadir over (group A) and below 0.4 μg/L (group B) at last follow-up.

ParameterGroup AGroup B
(GH-n ≥ 0.4 mcg/L)(GH-n < 0.4 mcg/L)

1129
BMI (Kg/m2)24.4 ± 4.628.6 ± 4.4ns
Impaired glucose metabolism (y/n)4/713/16ns
 IFG, IGT, DM (n)1/2/10/9/4
 Fasting glucose (mg/dL)85 ± 1497 ± 20ns
 Glucose at 120′ (mg/dL)138 ± 57128 ± 36ns
 HOMA-IR2.0 ± 1.72.1 ± 1.8ns
Blood hypertension (y/n)3/812/17ns
 SBP (mmHg)115 ± 15122 ± 12ns
 DBP (mmHg)74 ± 1179 ± 7ns
Cardio- and/or cerebrovascular disease (y/n)6/510/19ns
 Valvular heart disease44
 Acromegalic cardiomyopathy11
 Arrhythmias and cardiomyopathy05
 Acute myocardial infarction10
Malignancies (y/n)3/82/27ns
 Mammary carcinoma10
 Monoclonal gammopathy20
 Olfactory meningioma01
 Skin melanoma01
Colorectal disease 2/97/22ns
 Diverticula03
 Dolichocolon01
 Hyperplastic polyps02
 Adenomatous polyps2

IFG: impaired fasting glucose; IGT: impaired glucose tolerance; DM: diabetes mellitus; NS: not significant.
Low grade adenomatous tubular polyps, °serrated adenoma with low grade dysplasia.